Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission to the National Cancer Institute’s Genomic Data Commons (GDC).The Cancer Genome Atlas (TCGA) Project BackgroundThere are 230 distinct investigators that contributed
Read More
HealthQuest Capital Closes $440M Fund to Invest in Innovative Growth-Stage Companies
HealthQuest Capital, a Silicon Valley-based growth capital firm has closed a $440 million fund to invest growth-stage companies delivering innovation across all sectors of the healthcare industry to improve patient outcomes, enhance efficiency and reduce costs. Fund III was oversubscribed and closed at a hard cap. Target markets for Fund III include growth- and commercial-stage companies focusing on medical technologies, diagnostics, digital health, and innovative services.HealthQuest Capital
Read More
Roche Integrates Insulin Data from Novo Nordisk with Diabetes Management Solutions
Roche has signed a development and collaboration agreement with Novo Nordisk, a leader in innovating the therapy of diabetes and obesity. Under the terms of the development and collaboration agreement, the partners will integrate insulin data from Novo Nordisk's connected pen to Roche's open ecosystem, synchronizing with its suite of digital diabetes management solutions including mySugr.People with diabetes spend an average of one hour per day on self-care and have to make up to 50 therapy
Read More
Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine
Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the companies will leverage expertise in genomics and molecular information to enhance the development of perdsonalized medicines and care for patients with cancer.Foundation Medicine, based in Cambridge, Massachusetts, is a market leading molecular information company dedicated to a transformation in
Read More
Roche Acquires Oncology EHR Startup Flatiron Health for $1.9B
Roche has reached an agreement to acquire Flatiron Health, a NYC-based oncology EHR startup focused on accelerating cancer research and improving patient care for $1.9B. Under terms of the acquisition, Flatiron Health will continue its current business model, network of partnerships and overall objectives. The integrity of segregated patient protected health information will be preserved, as will dedicated sales and marketing, provider-facing and life science business activities. In addition,
Read More
Accenture, Roche Partner on Digital Health Integration for Tumor Board Solution
Accenture and Roche are teaming up on a new collaboration aimed at improving how oncology teams prepare for, conduct and document clinical treatment decisions for cancer patients in hospitals. Under the terms of the multi-year agreement, Accenture will provide digital health data integration services to Roche’s NAVIFY Tumor Board solution – fostering more efficient collaboration, reducing errors and giving care teams more time to evaluate individual patient cases.What Is A Tumor Board? A tumor
Read More
Roche Acquires Lab Data Analytics Platform Viewics
Roche, a pharmaceuticals and diagnostics focused on advancing science has announced an agreement to acquire Viewics, Inc., a laboratory business analytics platform. Under the terms of the agreement, Roche is acquiring all shares of the company. Financial details of the acquisition were not disclosed. As part of the acquisition, Viewics, Inc. will become an integral part of Roche and add further digital capabilities on top of Roche Diagnostics’ Integrated Core Lab offering to make faster
Read More
Accenture, Roche to Develop Data-Driven Analytics Platform for Diabetes Patients
Accenture is collaborating with Roche to develop a data-driven core analytics platform for Roche’s digital diabetes ecosystem. Under the terms of a five-year agreement, the new platform will be built on the Accenture Intelligent Patient Platform and offered to diabetes patients across North American, Europe and Asia, will allow Roche to gather and analyze data in a secure environment, generate new patient insights, and easily collaborate and integrate with its ecosystem partners and devices. At
Read More